

SHORT REPORT

ENDOMYOCARDIAL BIOPSY: A 21ST CENTURY DIAGNOSTIC TOOLROSA A.M.H. GOUVEIA^{1,2,3}, MARIA JOÃO ANDRADE⁴, CARLOS AGUIAR⁴, SÂNCIA RAMOS³¹Pathology and Histology, Faculty of Life Sciences, University of Madeira, Portugal²Clinical and Anatomical Pathology Laboratory (LANA), Funchal, Madeira, Portugal³Pathology, Hospital de Santa Cruz – CHLO, Lisboa, Portugal⁴Cardiology, Hospital de Santa Cruz – CHLO, Lisboa, Portugal

Key words: endomyocardial biopsy, native heart, cardiac graft, 21st century.

The question of the utility of *Endomyocardial Biopsy* (EMB) often and recurrently raises.

It is claimed that the image techniques provide identical results without the risks of an invasive procedure. It is a fact that the impressive technico-scientific development of cardiovascular imagological methodologies covers a broad spectrum of diagnosis. It is also a fact that endomyocardial biopsy is not completely risk-free. Yet, when performed by experienced professionals in reference centres, endomyocardial biopsies may disclose a final unexpected nosologic entity, confirm or exclude a proposed diagnosis and, even when not showing specific lesions in the examined samples, EMB may point to a multifocal involvement of the heart that eventually skipped the fragments collected [1, 2, 3].

Thus, it has a unique diagnostic value, as in post-cardiac transplant monitoring (Fig. 1A, B) [4, 5], myocarditis (Fig. 1C) [6, 7], cardiomyopathies, namely infiltrative (Fig. 1D-F) [8, 9], onco-cardiology (Fig. 1G, H) [10], among other pathological settings.

This letter aims to emphasize the up-to-date relevance of *Endomyocardial Biopsy* in the clinical cardiological workflow.

The authors declare no conflict of interest.

References

1. Veinot J. Endomyocardial Biopsy – when and how? *Cardiovascular Pathology* 2011; 20: 291-296.
2. Nguyen CT, Lee E, Luo H, et al. Echocardiographic guidance for diagnostic and therapeutic percutaneous procedures. *Cardiovasc Diagn Ther* 2011; 1: 11-36.
3. Gupta A, Aghdssi A. Endomyocardial Biopsy: Examining Indications and Trends in Use – More Native Heart Biopsy to Come? *Cardiology* 2019; 142: 102-104.
4. Nair V, Butany J. Heart transplant biopsies: interpretation and significance. *J Clin Pathol* 2010; 63: 12-20.
5. Gouveia RH, Vitorino E, Ramos S et al. C4d – The Witness of Humoral Rejection. *Transplantation Proceedings* 2009; 41: 866-867.
6. Moonen M, Lancellotti P. La Myocardite. *Rev Med Liège* 2018; 73: 269-276.
7. Zhou Z, Lopez H, Pérez G, et al. Toxoplasmosis and the Heart. *Curr Probl Cardiol* 2021; 46: 100741.
8. Ash S, Shorer E, Ramgobin D, et al. Cardiac amyloidosis – A review of current literature for the practicing physician. *Clin Cardiol* 2021; 44: 322-331.
9. Yamamoto H, Yockochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. *ESC Heart Failure* 2019; 6: 1128-1139.
10. Martino A, Re F, Barzaghi C et al. Occult primary cardiac lymphomas causing unexpected/sudden death or acute heart failure. *Virchows Arch* 2020; 477: 603-607.

Address for correspondence

Rosa A. M. H. Gouveia
Pathology and Histology
Faculty of Life Sciences
University of Madeira
Campus Universitário da Pentecada
9020-105, Funchal – Madeira, Portugal
e-mail: rhgouveia@mail.telepac.pt




Fig. 1. EMB and Heart Transplantation: A) Microscopic image of cardiac graft sample, stained with hæmatoxylin-eosin (HE, $\times 100$), showing interstitial oedema, linfo-histiocytic inflammatory infiltrate, which focally destroy myocytes, as in acute cellular rejection. B) A detail from the former sample immunomarked with C4d, revealing positivity in more than 50% of intra-myocardial small vessels, and thus acute humoral rejection (C4d, $\times 200$). C) EMB and Myocarditis – Histopathological view of myocardium with interstitial oedema, mixed inflammatory infiltrate (including mononuclear cells and polymorphonuclear neutrophils) and myocardial lesion, namely by the presence of intra-cellular microorganisms (\blacktriangleright) stained with the special technique Giemsa (Giemsa, $\times 100$), as in *Toxoplasmosis*. D, E, F) EMB and cardiomyopathies – Microscopic sections showing myocardial compression, distortion and replacement by extra-cellular amorphous deposits (*), stained with hæmatoxylin-eosin (HE $\times 100$) (D), with the special technique Congo Red (Congo Red $\times 100$) acquiring red colour (E) and the latter observed under polarized light, which displays *green-apple* bi-refringence (F), as documented in infiltrative/restrictive cardiomyopathy due to amyloid. G, H) EMB and onco-cardiopathology – G) Microscopic images of endomyocardial samples stained with hæmatoxylin-eosin (HE $\times 40$), some of which are densely occupied by neoplastic lymphoid cells (\blacktriangleleft), diffusely positive (in brown) for B cells immunomarker CD20 (CD20 $\times 100$) (H), as in diffuse large B cell non-hodgkin lymphoma